Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04126200 · ADVERSE EVENTS

Adverse events

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-05-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
Adverse events were not monitored/assessed during the screening phase (Day -30 to Day 0).
Other-event reporting threshold
0%

As prespecified in the study protocol, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected during the screening phase.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
All Screened Participants

Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.

0 / 00 / 00 / 0

Group identifiers: EG000: All Screened Participants

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      As prespecified in the study protocol, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected during the screening phase.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Participants with Relapsed/Refractory Multiple Myeloma (RRMM) were screened to be randomized in sub-studies of this master protocol.
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        All Screened Participants
      frequency Threshold
      0
      time Frame
      Adverse events were not monitored/assessed during the screening phase (Day -30 to Day 0).

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice